Label
No interactions expected
Color
Green
Green: Administer standard doses
| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Tenofovir alafenamide Sertraline 705 | Green: Administer standard doses | Administer standard doses | AUC decreased 4% |
50 mg once daily | Cmax increased 14%, AUC increased 9% |
||
| Tenofovir alafenamide RPV 704 | Green: Administer standard doses | Administer standard doses | Cmax increased 1%, AUC increased 1% |
25 mg once daily | Cmax decreased 7%, AUC increased 1%, Cmin increased 13% |
||
| Tenofovir alafenamide ATV 703 | Green: Administer standard doses | Administer standard doses | Cmax increased 77%, AUC increased 91% |
300 mg + 100mg ritonavir once daily | Cmax decreased 2%, AUC decreased 1% |
||
| Tenofovir alafenamide DRV/r 702 | Green: Administer standard doses | Administer standard doses | Cmax increased 42%, AUC increased 6% |
800 / 100 mg once daily | Cmax decreased 1%, AUC increased 1%, Cmin increased 13% |
||
| Lamivudine Ribavirin 700 | Green: Administer standard doses | Administer standard doses | No significant change |
800 mg daily | |||
| Lamivudine ATV 699 | Green: Administer standard doses | Administer standard doses | No significant change |
400 mg daily x 6 days | Not studied |
||
| Lamivudine Methadone 698 | Green: Administer standard doses | Administer standard doses | Not studied |
No significant change |
|||
| Lamivudine Entecavir 697 | Green: Administer standard doses | Administer standard doses | No significant change |
No significant change |
|||
| Lamivudine Buprenorphine / naloxone 696 | Green: Administer standard doses | Administer standard doses | 14 mg daily | No significant change |
|||
| Lamivudine Interferon alfa 695 | Green: Administer standard doses | Administer standard doses | No significant change |
10 MU three times weekly | No significant change |
||
| Lamivudine Adefovir 694 | Green: Administer standard doses | Administer standard doses | Not studied |
10 mg daily | No significant change |
||
| Lamivudine G/P 693 | Green: Administer standard doses | Administer standard doses | No significant change |
300 mg / 120 mg daily | GLE AUC decrease 25%, PIB AUC decrease 28% |
||
| Lamivudine TMP/SMX 692 | Green: Administer standard doses | Administer standard doses | Potentially increased lamivudine adverse effects |
Lamivudine AUC increased 44% |
160 mg / 800 mg daily x 5 days | Not studied |
|
| Emtricitabine Famciclovir 691 | Green: Administer standard doses | Administer standard doses | no significant change |
500 mg x 1 dose | no significant change |
||
| Emtricitabine Famciclovir 690 | Green: Administer standard doses | Administer standard doses | no significant change |
500 mg x 1 dose | no significant change |
||
| Emtricitabine TDF 689 | Green: Administer standard doses | Administer standard doses | Cmin increase 20% |
300 mg once daily x 7 days | No significant change |
||
| Emtricitabine TDF 688 | Green: Administer standard doses | Administer standard doses | Cmin increase 20% |
300 mg once daily x 7 days | No significant change |
||
| Emtricitabine TDF 687 | Green: Administer standard doses | Administer standard doses | Cmin increase 20% |
300 mg once daily x 7 days | No significant change |
||
| Emtricitabine TDF 686 | Green: Administer standard doses | Administer standard doses | Cmin increase 20% |
300 mg once daily x 7 days | No significant change |
||
| Emtricitabine TDF 685 | Green: Administer standard doses | Administer standard doses | Cmin increase 20% |
300 mg once daily x 7 days | No significant change |
||
| Emtricitabine TDF 684 | Green: Administer standard doses | Administer standard doses | Cmin increase 20% |
300 mg once daily x 7 days | no significant |
||
| Emtricitabine AZT, ZDV 683 | Green: Administer standard doses | Administer standard doses | No significant change |
300 mg once daily x 7 days | Cmax increased 17%, AUC increased 13% |
||
| Emtricitabine AZT, ZDV 682 | Green: Administer standard doses | Administer standard doses | No significant change |
300 mg once daily x 7 days | Cmax increased 17%, AUC increased 13% |
||
| Emtricitabine AZT, ZDV 681 | Green: Administer standard doses | Administer standard doses | No significant change |
300 mg once daily x 7 days | Cmax increased 17%, AUC increased 13% |
||
| Emtricitabine AZT, ZDV 680 | Green: Administer standard doses | Administer standard doses | No significant change |
300 mg once daily x 7 days | Cmax increased 17%, AUC increased 13% |
||
| Emtricitabine AZT, ZDV 679 | Green: Administer standard doses | Administer standard doses | No significant change |
300 mg once daily x 7 days | Cmax increased 17%, AUC increased 13% |
||
| Emtricitabine AZT, ZDV 678 | Green: Administer standard doses | Administer standard doses | No significant change |
300 mg once daily x 7 days | Cmax increased 17%, AUC increased 13% |
||
| Emtricitabine AZT, ZDV 677 | Green: Administer standard doses | Administer standard doses | No significant change |
300 mg once daily x 7 days | Cmax increased 17%, AUC increased 13% |
||
| Emtricitabine AZT, ZDV 676 | Green: Administer standard doses | Administer standard doses | No significant change |
300 mg once daily x 7 days | Cmax increased 17%, AUC increased 13% |
||
| Emtricitabine AZT, ZDV 675 | Green: Administer standard doses | Administer standard doses | No significant change |
300 mg once daily x 7 days | Cmax increased 17%, AUC increased 13% |
||
| Emtricitabine AZT, ZDV 674 | Green: Administer standard doses | Administer standard doses | No significant change |
300 mg once daily x 7 days | Cmax increased 17%, AUC increased 13% |
||
| Emtricitabine Famciclovir 673 | Green: Administer standard doses | Administer standard doses | Cmax decreased 10%; AUC decreased 7% |
500 mg x 1 dose | Cmax decreased 7%; AUC decreased 9% |
||
| Emtricitabine TDF 672 | Green: Administer standard doses | Administer standard doses | Cmin increase 20% |
300 mg once daily x 7 days | AUC increased 13%, Cmax increased 17% |
||
| Abacavir AZT, ZDV 671 | Green: Administer standard doses | Administer standard doses | Inconsistent effect across all dosing regimens; No effect on AUC with clinical abacavir dose of 300mg BID |
200 mg TID, 300 mg BID | No significant change |
||
| Abacavir AZT, ZDV 670 | Green: Administer standard doses | Administer standard doses | No significant change |
300 mg x 1 dose | Zidovudine Cmax decreased 20%; AUC no significant change |
||
| Abacavir 3TC 669 | Green: Administer standard doses | Administer standard doses | No significant change |
150 mg x 1 dose | Lamivudine Cmax decreased 35%; AUC decreased 15% |
||
| Abacavir Ethanol 668 | Green: Administer standard doses | Administer standard doses | Abacavir AUC increased 41%; half-life: increased 26%; Cmax increased 15%; T1 / 2 increased |
0.7 g / kg body weight | No significant change |
||
| Abacavir MMF, MPA 667 | Green: Administer standard doses | Administer standard doses | No significant change |
500 mg BID x 16 weeks | |||
| Rilpivirine SOF/VEL 657 | Green: Administer standard doses | Administer standard doses | Rilpivirine Cmin decreased 7% |
400 mg / 100 mg | |||
| Rilpivirine Famotidine 656 | Green: Administer standard doses | Administer standard doses | Rilpivirine Cmax increased 21% |
40 mg x 1 taken 4 hours after rilpivirine | |||
| Rilpivirine Famotidine 655 | Green: Administer standard doses | Administer standard doses | No significant change |
40 mg x 1 taken 12 hours before rilpivirine | |||
| Rilpivirine SOF 654 | Green: Administer standard doses | Administer standard doses | 400 mg x 1 | Sofosbuvir Cmax increased 21% |
|||
| Rilpivirine Chlorzoxazone 653 | Green: Administer standard doses | Administer standard doses | Rilpivirine AUC increased 25%; Cmin increased 18%; Cmax increased 17% |
500 mg x 1 | No significant change |
||
| Rilpivirine Sildenafil 652 | Green: Administer standard doses | Administer standard doses | No significant change |
50 mg x 1 | No significant change |
||
| Rilpivirine Simeprevir 651 | Green: Administer standard doses | Administer standard doses | Rilpivirine Cmin increased 25% |
150 mg daily x 11 days | No significant change |
||
| Rilpivirine Ethinyl estradiol / Norethindrone acetate 650 | Green: Administer standard doses | Administer standard doses | No significant change |
0.035 mg daily ethinyl estradiol with 1 mg norethindrone daily | Ethinyl estradiol Cmax increased 17%; Norethindrone: no significant change |
||
| Rilpivirine DTG 649 | Green: Administer standard doses | Administer standard doses | Rilpivirine Cmin increased 21% |
50 mg daily | Dolutegravir Cmin increased 22% |
||
| Rilpivirine Atorvastatin 648 | Green: Administer standard doses | Administer standard doses | No significant change |
40 mg daily | Atorvastatin Cmin decreased 15%; Cmax increased 35% |
||
| Rilpivirine Ketoconazole 647 | Green: Administer standard doses | Administer standard doses | Decreased ketoconazole effects |
Rilvpivirine AUC increased 49%; Cmin increased 76%; Cmax increased 30% |
400 mg daily | Ketoconazole AUC decreased 24%; Cmin decreased 66%; Cmax decreased 15% |
Monitor for failure of antifungal therapy |
| Nevirapine AZT, ZDV 602 | Green: Administer standard doses | Administer standard doses | No significant change |
100-200 mg TID | |||
| Nevirapine Daclatasvir 601 | Green: Administer standard doses | Administer standard doses | Cmin decreased 16% |
Rifabutin AUC increased 17%, metabolite AUC increased 24% |
|||
| Nevirapine Medroxyprogesterone acetate 600 | Green: Administer standard doses | Administer standard doses | 150 mg | Progesterone levels): no significant change |
|||
| Nevirapine Paclitaxel 599 | Green: Administer standard doses | Administer standard doses | No significant change |
100 mg / square meter infusion over 3 hours | Not studied |
||
| Nevirapine DTG 598 | Green: Administer standard doses | Administer standard doses | Nevirapine Cmin increased 22% |
50 mg daily | Dolutegravir AUC decreased 19%; Cmin decreased 34% |
||
| Nevirapine DRV 597 | Green: Administer standard doses | Administer standard doses | Potential for increased darunavir effects; Potential for increased nevirapine effects |
Nevirapine AUC increased 110%; Cmax increased 115%; Cmin increased 135%; half-live: decreased 52% (data compared to historical controls) |
400 mg BID with ritonavir 100 mg BID | Darunavir AUC increased 24%; Cmax increased 40% |
|
| Nevirapine RFB 596 | Green: Administer standard doses | Administer standard doses | Decreased antiviral efficacy |
AUC decreased 31% |
AUC increased 26% |
||
| Nevirapine RFB 595 | Green: Administer standard doses | Administer standard doses | Decreased antiviral efficacy |
No significant change in nevirapine Cmin |
150 or 300 mg daily | AUC increased 17%, Cmax increased 28% and 25-O-desacetyl-rifabutin AUC increased 24% |
|
| Nevirapine MVC 594 | Green: Administer standard doses | Administer standard doses | Nevirapine AUC no significant change |
300 mg single dose | Maraviroc Cmax increased 54% |
Use standard dose maraviroc. If coadministering with nevirapine plus a protease inhibitor, reduce dose of maraviroc to 150 mg BID |
|
| Nevirapine RTV 593 | Green: Administer standard doses | Administer standard doses | Nevirapine AUC decreased 40% |
600 mg BID | No significant change |
No dose adjustment necessary |
|
| Nevirapine Linagliptin 592 | Green: Administer standard doses | Administer standard doses | Possible decrease in antihyperglycemic effects |
Monitor glycemic control |
|||
| Nevirapine Atorvastatin 591 | Green: Administer standard doses | Administer standard doses | Decreased lipid effects |
Atorvastatin AUC decreased 32%-43% |
Monitor for statin efficacy. May need to increase atorvastatin dose |
||
| Nevirapine Trazodone 590 | Green: Administer standard doses | Administer standard doses | Decreased trazadone effects |
Monitor for signs and symptoms of depression and titrate trazadone to effect |
|||
| Nevirapine Sertraline 589 | Green: Administer standard doses | Administer standard doses | Decreased sertaline effects |
Monitor for signs and symptoms of depression and titrate sertaline to effect |
|||
| Nevirapine Escitalopram 588 | Green: Administer standard doses | Administer standard doses | Decreased escitalopram effects |
Monitor for signs and symptoms of depression and titrate escitalopram to effect |
|||
| Nevirapine Bupropion 587 | Green: Administer standard doses | Administer standard doses | Decreased bupropion effects |
Monitor for signs and symptoms of depression and titrate bupropion to effect |
|||
| Nevirapine Fluconazole 586 | Green: Administer standard doses | Administer standard doses | Potential for increased nevirapine effects |
200 mg three times weekly | Monitor for nevirapine toxicity |
||
| Nevirapine Fluconazole 585 | Green: Administer standard doses | Administer standard doses | Increased nevirapine effects |
200 mg daily x 40 days | No significant change |
Monitor for nevirapine toxicity |
|
| Nevirapine Isavuconazole 584 | Green: Administer standard doses | Administer standard doses | Possible decreased Isavuconazole levels |
monitor for isravucanazole concentrations and anti fungal response |
|||
| Etravirine Omeprazole 535 | Green: Administer standard doses | Administer standard doses | Etravirine AUC increased 41% |
40 mg daily x 11 days | |||
| Etravirine Ranitidine 534 | Green: Administer standard doses | Administer standard doses | No significant change |
150 mg BID x 11 days | |||
| Etravirine Methadone 533 | Green: Administer standard doses | Administer standard doses | 60-130 mg daily | R-methadone: no significant effect; S-methadone: no significant effect |
|||
| Etravirine RAL 532 | Green: Administer standard doses | Administer standard doses | Etravirine Cmin increased 17% |
400 mg BID | Raltegravir Cmin decreased 34% |
||
| Etravirine Paroxetine 531 | Green: Administer standard doses | Administer standard doses | No significant change |
20 mg daily | No significant change |
||
| Etravirine Ethinyl estradiol / Norethindrone acetate 530 | Green: Administer standard doses | Administer standard doses | 0.035 mg EE / 1 mg NE daily | Ethinyl estradiol AUC increased 22%; Cmax increased 33%; Norethindrone Cmin decreased 22% |
|||
| Etravirine DRV 529 | Green: Administer standard doses | Administer standard doses | Etravirine AUC increased 80%; Cmax increased 81%; Cmin increased 67% (compared to etravirine 100 mg BID) |
Darunavir AUC increased 15% |
|||
| Etravirine DRV 528 | Green: Administer standard doses | Administer standard doses | Etravirine AUC decreased 37%; Cmax decreased 32%; Cmin decreased 49% |
600 mg BID with 100 mg ritonavir BID | No significant change |
||
| Etravirine Voriconazole 527 | Green: Administer standard doses | Administer standard doses | Potential for increased etravirine effects |
Etravirine AUC increased 36%; Cmin increased 52%; Cmax increased 26% |
200 mg BID | Voriconazole Cmin increased 23% |
|
| Etravirine Saxagliptin 526 | Green: Administer standard doses | Administer standard doses | Possible decrease in antihyperglycemic effects |
Monitor glycemic control |
|||
| Etravirine Linagliptin 525 | Green: Administer standard doses | Administer standard doses | Possible decrease in antihyperglycemic effects |
Monitor glycemic control |
|||
| Etravirine Midazolam 524 | Green: Administer standard doses | Administer standard doses | decreased levels of midazolam |
Midozolam AUC decreased 31%; active metabolite Cmax increased 57% |
Monitor for theraputive effectiveness of midazolam |
||
| Etravirine Sildenafil 523 | Green: Administer standard doses | Administer standard doses | Decreased sildenafil effects |
50 mg x 1 | Sildenafil AUC decreased 57%; Cmax decreased 45% |
Monitor for sildenafil efficacy and titrate to effect |
|
| Etravirine Fluconazole 522 | Green: Administer standard doses | Administer standard doses | Increased etravirine effects |
Etravirine AUC increased 86%; Cmax increased 75%; Cmin increased 109% |
200 mg QAM | No significant change |
Monitor for fluconazole associated toxicities |
| Etravirine Posaconazole 521 | Green: Administer standard doses | Administer standard doses | Not studied (may increase etravirine levels) |
Not studied |
Monitor for etravirine related toxicities |
||
| Efavirenz RPT 431 | Green: Administer standard doses | Administer standard doses | Efavirenz AUC decreased 14%; Cmin decreased 15% |
900 mg Q week | |||
| Efavirenz Famotidine 430 | Green: Administer standard doses | Administer standard doses | No significant change |
40 mg x 1 dose | |||
| Efavirenz AZT, ZDV 429 | Green: Administer standard doses | Administer standard doses | No significant change |
300 mg Q12h x 14 days | |||
| Efavirenz Aluminum and magnesium hydroxide antacid 428 | Green: Administer standard doses | Administer standard doses | No significant change |
30 mL x 1 dose | |||
| Efavirenz SOF 427 | Green: Administer standard doses | Administer standard doses | 400 mg x 1 | Sofosbuvir Cmax decreased 19% |
|||
| Efavirenz Medroxyprogesterone acetate 426 | Green: Administer standard doses | Administer standard doses | Efavirenz AUC no significant change |
150 mg | Progesterone levels: no significant change |
||
| Efavirenz Valproic acid 425 | Green: Administer standard doses | Administer standard doses | Efavirenz Cmin no significant change; Cmax no significant change; AUC no significant change; half-life: decreased 22% |
250 mg BID x 7 days | No significant change |
||
| Efavirenz 3TC 424 | Green: Administer standard doses | Administer standard doses | Not studied |
150 mg Q12H x 14 days | No significant change |
||
| Efavirenz NFV 423 | Green: Administer standard doses | Administer standard doses | 750 mg TID | Nelfinavir clearance: no significant changeM8 clearance: increased 43% |
|||
| Efavirenz Lorazepam 422 | Green: Administer standard doses | Administer standard doses | 2 mg x 1 dose | Lorazepam AUC no significant change; Cmax increased 16% |
|||
| Efavirenz Lorazepam 421 | Green: Administer standard doses | Administer standard doses | 2 mg x 1 dose | Lorazepam AUC no significant change; Cmax increased 16% |
|||
| Efavirenz Cetirizine 420 | Green: Administer standard doses | Administer standard doses | No significant change |
10 mg x 1 dose | Cetirizine Cmax decreased 24% |
||
| Efavirenz Cetirizine 419 | Green: Administer standard doses | Administer standard doses | No significant change |
10 mg x 1 dose | Cetirizine Cmax decreased 24% |
||
| Efavirenz Z-Pak 418 | Green: Administer standard doses | Administer standard doses | No significant change |
600 mg x 1 dose | Azithromycin AUC no significant change; Cmax increased 22% |
||
| Efavirenz Z-Pak 417 | Green: Administer standard doses | Administer standard doses | No significant change |
600 mg x 1 dose | Azithromycin AUC no significant change; Cmax increased 22% |
||
| Efavirenz LDV/SOF 416 | Green: Administer standard doses | Administer standard doses | 90 / 400 mg daily x 14 days | Ledipasvir / Sofosbuvir auc decreased 34%, Cmin decreased 34%, Cmax decreased 34%. |
|||
| Efavirenz LDV/SOF 415 | Green: Administer standard doses | Administer standard doses | 90 / 400 mg daily x 14 days | Ledipasvir / Sofosbuvir auc decreased 34%, Cmin decreased 34%, Cmax decreased 34%. |
